Further Evidence for Early Healing with the SYNERGY™ Stent
How does SYNERGY compare with other stents regarding endothelial cell coverage, endothelial cell function, and thrombogenicity?
The SYNERGY everolimus-eluting stent (EES) was designed to enhance optimal healing with a 74µm strut coated with an ultra-thin abluminal bioabsorbable PLGA polymer. Clinical results from multiple investigator-sponsored research programs using OCT to assess healing have shown high percentages of strut coverage at early time points with SYNERGY supporting the goal of improved healing. Pre-clinical studies provide additional evidence to support optimized healing by not only detecting percent strut coverage but also by providing insight to the type of cell covering the strut. Specifically, functional endothelial cells are important for intravascular healing as they provide a barrier to excess neointimal growth and thrombus formation. Using a cell assay for human endothelial cell growth, it has been shown that abluminal bioabsorble PLGA polymer EES has significantly improved endothelialization over a conformal bioabsorbable polymer and a conformal permanent polymer EES. This study has also shown that EES with abluminal PLGA coatings have similar percent cell coverage to a PtCr bare metal stent platform.
Better Endothelial Cell Strut Coverage with the SYNERGY Stent
% Endothelial Cell (EC) Coverage at 21 Days in Cell Assay
In addition to endothelial cell coverage, endothelial cell function is also critical for intravascular healing. The SYNERGY Stent was shown to have improved endothelial cell function over the PROMUS Element Stent in a pre-clinical assessment.Greater Endothelial Cell Function with the SYNERGY Stent
Endothelial Cell (EC) Function
In a pre-clinical evaluation, SYNERGY displays greater localization of VE-Cadherin at cell junctions indicating improved EC function. Green stain indicates functional endothelial cells.
Thrombogenicity is also important to healing.Results from ex vivo porcine AV shunt model show the SYNERGY Stent (74µm strut thickness) has reduced acute thrombogenicity when compared to BioMatrix (120µm strut thickness) or BVS (157µm strut thickness).Reduced Thrombogenicity with the SYNERGY Stent
Red stain indicated thrombus formation assessed by immunofluorescence staining for platelet marker CD61 after 1 hour in ex vivo porcine AV shunt model